Giovanni Penco

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas et al. · The Lancet · 2018 · 371 citations · Full text

Hiv/aids Counselling, Treatment And Prevention, Week 48 +14

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

Antonella Castagna, Franco Maggiolo, Giovanni Penco et al. · The Journal of Infectious Diseases · 2014 · 322 citations · Full text

Tenofovir renal safety in HIV-infected patients: Results from the SCOLTA Project

Giordano Madeddu, Paolo Bonfanti, Giuseppe Vittorio De Socio et al. · Biomedicine & Pharmacotherapy · 2007 · 72 citations

Urology, Scolta Project, Tenofovir Renal Safety +7

Identifying HIV patients with an unfavorable cardiovascular risk profile in the clinical practice: Results from the SIMONE study

Giuseppe Vittorio De Socio, Giustino Parruti, Tiziana Quirino et al. · Journal of Infection · 2008 · 56 citations

Sexual Health, Epidemiology, Cardiovascular Epidemiology +15

Is Metabolic Syndrome Associated to HIV Infection Per Se? Results from the HERMES Study

Paolo Bonfanti, Giuseppe Vittorio De Socio, P Marconi et al. · Current HIV Research · 2010 · 54 citations